The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.
 
Jacob Stephen Thomas
Consulting or Advisory Role - Kura Oncology; Tasly Pharmaceuticals
 
Jennifer Eva Selfridge
Research Funding - BioAtla (Inst); Cue Biopharma (Inst); Pfizer (Inst); Trishula Therapeutics (Inst); Vigeo Therapeutics (Inst)
 
Costantine Albany
No Relationships to Disclose
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; OncoSec; Regeneron; Roche
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Exelixis; Merck
Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Inderjit Mehmi
Speakers' Bureau - Bristol-Myers Squibb; Immunocore
 
Vineet Kwatra
Consulting or Advisory Role - Janssen; Roche
Speakers' Bureau - Bayer; GlaxoSmithKline
Travel, Accommodations, Expenses - Janssen
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen; Ascendis Pharma; Astellas Amgen BioPharama; Bristol Myers Squibb Foundation; Genmab; Immunocore; Merck; Nektar; Neon Therapeutics; Novartis; Regeneron; Vaccinex; Xencor
Research Funding - Astellas Amgen BioPharama; BioAtla; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Checkmate Pharmaceuticals; Dragonfly Data Ventures; F-Star; Genentech; Kite, a Gilead Company; Merck; Neon Therapeutics; OncoC4; Pfizer; Plexxikon; Vaccinex; Vedanta Biosciences; Xencor
 
Paul L. de Souza
No Relationships to Disclose
 
Judith Dubal Llorin-Sangalang
Employment - BioAtla, Inc.
 
Kartik Aysola
Employment - BioAtla, Inc.
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)